Company · celerion-98954fc9

Celerion

4 sourcescompanies-2026-11-14-0.1.0

Cite this record

ConductScience Library. Celerion. Companies, record celerion-98954fc9. Release companies-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/companies/celerion-98954fc9

On this page

Company

The name as ClinicalTrials.gov gives it. A company is a name ClinicalTrials.gov classes as industry, and spellings that differ only in case or spacing are one; no subsidiary is folded into a parent. A trial of two phases counts in both, and recruiting trials count as active.

Name: Celerion
Trials: 86
As lead sponsor: 0
As collaborator: 86
Recruiting: 1
Active, recruiting or not: 1
Completed: 83
Stopped early, withdrawn or suspended: 0
Posted results: 13
Trials by phase: Phase 1 64, Phase 2 7
Drugs its trials test: 62
Comparisons calculated in its trials: 4
First trial registered: 2010-11-30
Last update: 2026-07-31

Source ClinicalTrials.gov

Pipeline62

The drugs its trials test, by the trial links the pipelines release's checks show. The phase is the highest phase those trials registered on ClinicalTrials.gov, not a development stage. Highest phase first, then the most trials.

Drug	Highest phase registered	Trials	Targets	Mechanism	In Drugs and targets	Source
TREOSULFAN	Phase 2	2			https://conductscience.org/library/drugs/CHEMBL455186	Open Targets
BUSULFAN	Phase 2	1			https://conductscience.org/library/drugs/CHEMBL820	Open Targets
FLUDARABINE	Phase 2	1			https://conductscience.org/library/drugs/CHEMBL1568	Open Targets
TESTOSTERONE UNDECANOATE	Phase 2	1	AR	Androgen Receptor agonist	https://conductscience.org/library/drugs/CHEMBL2107067	Open Targets
THIOTEPA	Phase 2	1			https://conductscience.org/library/drugs/CHEMBL671	Open Targets
TRICAPRILIN	Phase 1	4			https://conductscience.org/library/drugs/CHEMBL1406148	Open Targets
MOXIFLOXACIN	Phase 1	3			https://conductscience.org/library/drugs/CHEMBL32	Open Targets
RESMETIROM	Phase 1	3	THRB	Thyroid hormone receptor beta-1 agonist	https://conductscience.org/library/drugs/CHEMBL3261331	Open Targets
ACORAMIDIS	Phase 1	2	TTR	Transthyretin stabiliser	https://conductscience.org/library/drugs/CHEMBL3940890	Open Targets
DANICOPAN	Phase 1	2	CFD	Complement factor D inhibitor	https://conductscience.org/library/drugs/CHEMBL4250860	Open Targets

1 to 10 of 62

See all 62 pipeline

Trials86

The trials that name the company as lead sponsor or collaborator, newest registered first. Results posted are as ClinicalTrials.gov gave them on the day of the sponsors capture.

Trial	Title	Role	Phase	Status	Type	Participants	Start	Results first posted	Drugs	In Trials	Source
NCT07673900	Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants	Collaborator	Phase 1	Recruiting	Interventional	62	2026-06-15			https://conductscience.org/library/trials/NCT07673900	ClinicalTrials.gov
NCT06971900	GATEWAY: A Phase 2a Study of PORT-77 in Adults With Erythropoietic Protoporphyria	Collaborator	Phase 2	Completed	Interventional	28	2025-04-04			https://conductscience.org/library/trials/NCT06971900	ClinicalTrials.gov
NCT06691386	Nicotine Pharmacokinetics and Subjective Effects of Oral Nicotine Products Relative to Smokeless Tobacco in Adult Users	Collaborator	Not applicable	Completed	Interventional	64	2023-02-06			https://conductscience.org/library/trials/NCT06691386	ClinicalTrials.gov
NCT06625814	A Study of Levothyroxine and Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-028)	Collaborator	Phase 1	Completed	Interventional	28	2024-07-08		ENLICITIDE DECANOATE, LEVOTHYROXINE	https://conductscience.org/library/trials/NCT06625814	ClinicalTrials.gov
NCT06597760	A Clinical Study to Assess the Effect of Enlicitide on How the Body Processes Digoxin in Healthy Adult Participants (MK-0616-031)	Collaborator	Phase 1	Completed	Interventional	24	2024-10-07		ENLICITIDE	https://conductscience.org/library/trials/NCT06597760	ClinicalTrials.gov
NCT06356610	Pharmacokinetic and Subjective Effects of Heated Tobacco Products	Collaborator	Not applicable	Completed	Interventional	80	2024-02-06	2026-03-27		https://conductscience.org/library/trials/NCT06356610	ClinicalTrials.gov
NCT06179290	Changes in Biomarker of Exposure in Adults Who Smoke Cigarettes Switching From Cigarettes to Heated Tobacco Products	Collaborator	Not applicable	Completed	Interventional	921	2023-10-02	2026-05-27		https://conductscience.org/library/trials/NCT06179290	ClinicalTrials.gov
NCT05927649	A TQTc Study for Omaveloxolone	Collaborator	Phase 1	Completed	Interventional	30	2023-07-11		OMAVELOXOLONE	https://conductscience.org/library/trials/NCT05927649	ClinicalTrials.gov
NCT05909644	An Open-label DDI Study of Omaveloxolone in Healthy Subjects	Collaborator	Phase 1	Completed	Interventional	20	2023-07-05		EFAVIRENZ, OMAVELOXOLONE	https://conductscience.org/library/trials/NCT05909644	ClinicalTrials.gov
NCT05428696	Safety and Tolerability, PK, and PD Study of Single and Multiple ALXN2080 Doses in Healthy Participants	Collaborator	Phase 1	Completed	Interventional	90	2022-09-12		ZORACOPAN	https://conductscience.org/library/trials/NCT05428696	ClinicalTrials.gov

1 to 10 of 86

See all 86 trials

Conditions48

The conditions its trials name, as the trials write them, with case and spacing folded. The most trials first.

Condition	Trials
Healthy	30
Healthy Volunteers	12
Tobacco Use	9
Smoking	4
Cystic Fibrosis	3
Healthy Subjects	2
Poliomyelitis	2
TQT Study	2
Acute Lymphoblastic Leukaemias (ALL)	1
Acute Myeloid Leukaemias (AML)	1

1 to 10 of 48Source ClinicalTrials.gov

See all 48 conditions

Partners79

The other organizations its trials name, as lead sponsor or collaborator, with the class ClinicalTrials.gov gives each. The most trials shared first. A partner that is a company opens its own record.

Organization	Class	Trials shared	In Companies	Source
Alexion Pharmaceuticals, Inc.	Industry	6	https://conductscience.org/library/companies/alexion-pharmaceuticals-inc-40a2bfe8	ClinicalTrials.gov
RAI Services Company	Industry	6	https://conductscience.org/library/companies/rai-services-company-b315a990	ClinicalTrials.gov
Cerecin	Industry	4	https://conductscience.org/library/companies/cerecin-e0682331	ClinicalTrials.gov
Altria Client Services LLC	Industry	3	https://conductscience.org/library/companies/altria-client-services-llc-ca171998	ClinicalTrials.gov
Madrigal Pharmaceuticals, Inc.	Industry	3	https://conductscience.org/library/companies/madrigal-pharmaceuticals-inc-df9393a9	ClinicalTrials.gov
Merck Sharp & Dohme LLC	Industry	3	https://conductscience.org/library/companies/merck-sharp-dohme-llc-d93bce8d	ClinicalTrials.gov
Syneos Health	Other	3		ClinicalTrials.gov
Achillion, a wholly owned subsidiary of Alexion	Industry	2	https://conductscience.org/library/companies/achillion-a-wholly-owned-subsidiary-of-alexion-32334566	ClinicalTrials.gov
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Industry	2	https://conductscience.org/library/companies/afferent-pharmaceuticals-inc-a-subsidiary-of-merck-co-inc-ra-eaac4a86	ClinicalTrials.gov
Bill and Melinda Gates Foundation	Other	2		ClinicalTrials.gov

1 to 10 of 79

See all 79 partners

Data dates

The date of each source this release read.

Sponsors and results posted: 2026-11-14; ClinicalTrials.gov
Trials' registrations: 2026-11-12; ClinicalTrials.gov
Drug links and targets: 2026-09-18; Open Targets
Comparisons: 2026-03-23; Trial comparisons

Sources 4

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL
ClinicalTrials.govNo license stated
Open TargetsCC0 1.0

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBLCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this company from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/companies/v1/celerion-98954fc9

GET https://conductscience.org/api/companies/v1/celerion-98954fc9/pipeline?page=2

API reference For AI assistants